Head to head

Motus AY vs Motus AZ+ (2026)

Compare purchase costs, running costs and the evidence behind each device.

Read the comparison overview

Purchase cost: The catalog lists $120k–$160k for Motus AZ+. No new-price range is on file for Motus AY. Check the source notes and request current quotes.
Practice fit: Both are listed under dual-wavelength (in-motion). Check each model’s US regulatory status and labeled indications for your intended use.

Device A

Dual-wavelength (in-motion)

View full device profile →

Device B

Dual-wavelength (in-motion)

View full device profile →

Price comparison

Price comparison: DEKA Motus AY vs DEKA Motus AZ+
Attribute	DEKA Motus AY	DEKA Motus AZ+
New price range	Not published	$120k–$160kSource not documented
Used asking range	$55k–$85kSource not documented	$80k–$110kSource not documented
Payback calculator	View ROI calculator	View ROI calculator
Next step	Explore this model’s specs and owner reviews. For new-equipment inquiries, browse current models. Browse current models

New price range

DEKA Motus AY: Not published
DEKA Motus AZ+: $120k–$160kSource not documented

Used asking range

DEKA Motus AY: $55k–$85kSource not documented
DEKA Motus AZ+: $80k–$110kSource not documented

Payback calculator

DEKA Motus AY: View ROI calculator
DEKA Motus AZ+: View ROI calculator

Next step

DEKA Motus AY

Explore this model’s specs and owner reviews. For new-equipment inquiries, browse current models.

Browse current models

DEKA Motus AZ+

Supplies & running costs

Supplies & running costs: DEKA Motus AY vs DEKA Motus AZ+
Attribute	DEKA Motus AY	DEKA Motus AZ+
Supplies & restrictions	Supply details not yet documented. View running-cost details	No per-treatment consumables — gel and eventual sapphire-tip wear; a few thousand a year in maintenance reserve. Source not documented View running-cost details

Supplies & restrictions

DEKA Motus AY: Supply details not yet documented.
View running-cost details
DEKA Motus AZ+: No per-treatment consumables — gel and eventual sapphire-tip wear; a few thousand a year in maintenance reserve.
Source not documented
View running-cost details

FDA status & indications

FDA status & indications: DEKA Motus AY vs DEKA Motus AZ+
Attribute	DEKA Motus AY	DEKA Motus AZ+
FDA status & indication	FDA ClearedK181486 Read FDA indication wording “Alexandrite 755nm laser source: Temporary hair reduction. Stable long-term or permanent hair reduction through selective targeting of melanin in hair follicles. Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6,9, and 12 months after the completion of a treatment regime, on all skin types (Fitzpatrick I – VI) including tanned skin. Treatment of benign pigmented lesions. Treatment of wrinkles. Photocoagulation of benign dermatological vascular lesions (such as port-wine stains, hemangiomas, telangiectasias). Nd:YAG 1064nm laser source: Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of PFB . The lasers are indicated on all Skin Types Fitzpatrick I-VI including tanned skin. Photocoagulation and hemostasis of benign pigmented and benign vascular lesions, such as but not limited to port wine stains, hemangioma, warts, teleangiectasia, rosacea, venus lake, leg veins and spider veins. Coagulation and hemostasis of soft tissue. Benign pigmented lesions such as, but not limited to, lentigos, (age spots), solar lentigos (sun spots), cafe au lait macules, seborrheic keratosis, nevi, cloasma, verrucae, skin tags, keratosis and plaques. The laser is indicated for benign pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments. The laser is also indicated for the reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. Treatment of wrinkles.”	FDA ClearedK211821, K162886, K181486 Read FDA indication wording “Alexandrite 755nm laser source: Temporary hair reduction. Stable long-term or permanent hair reduction through selective targeting of melanin in hair follicles. Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6,9, and 12 months after the completion of a treatment regime, on all skin types (Fitzpatrick I – VI) including tanned skin. Treatment of benign pigmented lesions. Treatment of wrinkles. Photocoagulation of benign dermatological vascular lesions (such as port-wine stains, hemangiomas, telangiectasias). Nd:YAG 1064nm laser source: Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of PFB. The lasers are indicated on all Skin Types Fitzpatrick I-VI including tanned skin. Photocoagulation and hemostasis of benign pigmented and benign vascular lesions, such as but not limited to port wine stains, hemangioma, warts, teleangiectasia, rosacea, venus lake, leg veins and spider veins. Coagulation and hemostasis of soft tissue. Benign pigmented lesions such as, but not limited to, lentigos, (age spots), solar lentigos (sun spots), cafe au lait macules, seborrheic keratosis, nevi, cloasma, verrucae, skin tags, keratosis and plaques. The laser is indicated for benign pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments. The laser is also indicated for the reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. Treatment of wrinkles.”

FDA status & indication

DEKA Motus AY: FDA ClearedK181486
Read FDA indication wording
“Alexandrite 755nm laser source: Temporary hair reduction. Stable long-term or permanent hair reduction through selective targeting of melanin in hair follicles. Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6,9, and 12 months after the completion of a treatment regime, on all skin types (Fitzpatrick I – VI) including tanned skin. Treatment of benign pigmented lesions. Treatment of wrinkles. Photocoagulation of benign dermatological vascular lesions (such as port-wine stains, hemangiomas, telangiectasias). Nd:YAG 1064nm laser source: Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of PFB . The lasers are indicated on all Skin Types Fitzpatrick I-VI including tanned skin. Photocoagulation and hemostasis of benign pigmented and benign vascular lesions, such as but not limited to port wine stains, hemangioma, warts, teleangiectasia, rosacea, venus lake, leg veins and spider veins. Coagulation and hemostasis of soft tissue. Benign pigmented lesions such as, but not limited to, lentigos, (age spots), solar lentigos (sun spots), cafe au lait macules, seborrheic keratosis, nevi, cloasma, verrucae, skin tags, keratosis and plaques. The laser is indicated for benign pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments. The laser is also indicated for the reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. Treatment of wrinkles.”
DEKA Motus AZ+: FDA ClearedK211821, K162886, K181486
Read FDA indication wording
“Alexandrite 755nm laser source: Temporary hair reduction. Stable long-term or permanent hair reduction through selective targeting of melanin in hair follicles. Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6,9, and 12 months after the completion of a treatment regime, on all skin types (Fitzpatrick I – VI) including tanned skin. Treatment of benign pigmented lesions. Treatment of wrinkles. Photocoagulation of benign dermatological vascular lesions (such as port-wine stains, hemangiomas, telangiectasias). Nd:YAG 1064nm laser source: Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of PFB. The lasers are indicated on all Skin Types Fitzpatrick I-VI including tanned skin. Photocoagulation and hemostasis of benign pigmented and benign vascular lesions, such as but not limited to port wine stains, hemangioma, warts, teleangiectasia, rosacea, venus lake, leg veins and spider veins. Coagulation and hemostasis of soft tissue. Benign pigmented lesions such as, but not limited to, lentigos, (age spots), solar lentigos (sun spots), cafe au lait macules, seborrheic keratosis, nevi, cloasma, verrucae, skin tags, keratosis and plaques. The laser is indicated for benign pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments. The laser is also indicated for the reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. Treatment of wrinkles.”

Which chains run each

Which chains run each: DEKA Motus AY vs DEKA Motus AZ+
Attribute	DEKA Motus AY	DEKA Motus AZ+
Chain adoption	1 recorded pairing	0 recorded pairings
Chains using it	Sona MedSpa(Confirmed)	—
Approved reviews	0	0

Chain adoption

DEKA Motus AY: 1 recorded pairing
DEKA Motus AZ+: 0 recorded pairings

Chains using it

DEKA Motus AY: Sona MedSpa(Confirmed)
DEKA Motus AZ+: —

Approved reviews

DEKA Motus AY: 0
DEKA Motus AZ+: 0

Specs and platform

Specs and platform: DEKA Motus AY vs DEKA Motus AZ+
Attribute	DEKA Motus AY	DEKA Motus AZ+
Manufacturer	DEKA	DEKA
Built by (OEM)	DEKA M.E.L.A. S.r.l.	DEKA M.E.L.A. S.r.l.
Category	Dual-wavelength (in-motion)	Dual-wavelength (in-motion)
Technology	755nm alex + 1064nm Nd:YAG Moveo (Alexandrite)	755/1064nm Moveo, higher power (Alexandrite)
Launch year	2019	2022
Status	Discontinued	Current
Manufacturing relationship evidence	No separate manufacturing-relationship record linked.	No separate manufacturing-relationship record linked.

Manufacturer

DEKA Motus AY: DEKA
DEKA Motus AZ+: DEKA

Built by (OEM)

DEKA Motus AY: DEKA M.E.L.A. S.r.l.
DEKA Motus AZ+: DEKA M.E.L.A. S.r.l.

Current alternatives

Current catalog models in related categories. Confirm availability and configuration with the supplier.

Lumenis OptiLIGHT

IPL platform

New-equipment price not yet documented.

Cutera Xeo

Multi-app platform

New-equipment price reference

$80k–$120k

Source not documented

Check the profile for configuration and price details.

Cutera Excel HR

Dual-wavelength laser

New-equipment price reference

$95k–$135k

Source not documented

Check the profile for configuration and price details.

InMode Triton

Triple-wavelength diode

New-equipment price reference

$100k–$135k

Source not documented

Check the profile for configuration and price details.

Get a free recommendation Browse by goal

Device and company names are trademarks of their respective owners. The Aesthetic Index is not affiliated with or endorsed by any manufacturer, distributor or lender named here, except as disclosed. Price figures are references, not current offers. Check each device’s source notes. Not medical, legal or regulatory advice.